1
|
Goodwin JM, Walkup WG, Hooper K, Li T, Kishi-Itakura C, Ng A, Lehmberg T, Jha A, Kommineni S, Fletcher K, Garcia-Fortanet J, Fan Y, Tang Q, Wei M, Agrawal A, Budhe SR, Rouduri SR, Baird D, Saunders J, Kiselar J, Chance MR, Ballabio A, Appleton BA, Brumell JH, Florey O, Murphy LO. GABARAP sequesters the FLCN-FNIP tumor suppressor complex to couple autophagy with lysosomal biogenesis. Sci Adv 2021; 7:eabj2485. [PMID: 34597140 PMCID: PMC10938568 DOI: 10.1126/sciadv.abj2485] [Citation(s) in RCA: 41] [Impact Index Per Article: 13.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 04/29/2021] [Accepted: 08/11/2021] [Indexed: 05/28/2023]
Abstract
Adaptive changes in lysosomal capacity are driven by the transcription factors TFEB and TFE3 in response to increased autophagic flux and endolysosomal stress, yet the molecular details of their activation are unclear. LC3 and GABARAP members of the ATG8 protein family are required for selective autophagy and sensing perturbation within the endolysosomal system. Here, we show that during the conjugation of ATG8 to single membranes (CASM), Parkin-dependent mitophagy, and Salmonella-induced xenophagy, the membrane conjugation of GABARAP, but not LC3, is required for activation of TFEB/TFE3 to control lysosomal capacity. GABARAP directly binds to a previously unidentified LC3-interacting motif (LIR) in the FLCN/FNIP tumor suppressor complex and mediates sequestration to GABARAP-conjugated membrane compartments. This disrupts FLCN/FNIP GAP function toward RagC/D, resulting in impaired substrate-specific mTOR-dependent phosphorylation of TFEB. Thus, the GABARAP-FLCN/FNIP-TFEB axis serves as a molecular sensor that coordinates lysosomal homeostasis with perturbations and cargo flux within the autophagy-lysosomal network.
Collapse
Affiliation(s)
| | - Ward G. Walkup
- Casma Therapeutics, 400 Technology Sq, Cambridge, MA 02139, USA
| | - Kirsty Hooper
- Signalling Programme, Babraham Institute, Cambridge, UK
| | - Taoyingnan Li
- Department of Molecular Genetics, University of Toronto, Toronto, ON M5S 1A8, Canada
- Cell Biology Program, Hospital for Sick Children, Toronto, ON M5G 1X8, Canada
| | | | - Aylwin Ng
- Casma Therapeutics, 400 Technology Sq, Cambridge, MA 02139, USA
| | | | - Archana Jha
- Casma Therapeutics, 400 Technology Sq, Cambridge, MA 02139, USA
| | | | | | | | | | | | | | - Asmita Agrawal
- Sai Life Sciences Limited, Pune 411057, Maharashtra, India
| | - Sagar R. Budhe
- Sai Life Sciences Limited, Pune 411057, Maharashtra, India
| | | | - Dan Baird
- Casma Therapeutics, 400 Technology Sq, Cambridge, MA 02139, USA
| | - Jeff Saunders
- Casma Therapeutics, 400 Technology Sq, Cambridge, MA 02139, USA
| | | | - Mark R. Chance
- NEO Proteomics Inc., Cleveland, OH 44106, USA
- School of Medicine, Case Western Reserve University, Cleveland, OH 44016, USA
| | - Andrea Ballabio
- Telethon Institute of Genetics and Medicine (TIGEM), Naples, Italy
- Medical Genetics Unit, Department of Medical and Translational Science, Federico II University, Naples, Italy
- Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX 77030, USA
- Jan and Dan Duncan Neurological Research Institute, Texas Children’s Hospital, Houston, TX 77030, USA
- SSM School for Advanced Studies, Federico II University, Naples, Italy
| | | | - John H. Brumell
- Department of Molecular Genetics, University of Toronto, Toronto, ON M5S 1A8, Canada
- Cell Biology Program, Hospital for Sick Children, Toronto, ON M5G 1X8, Canada
- Institute of Medical Science, University of Toronto, Toronto, ON M5S 1A8, Canada
- SickKids IBD Centre, Hospital for Sick Children, Toronto, ON M5G 0A4, Canada
| | - Oliver Florey
- Signalling Programme, Babraham Institute, Cambridge, UK
| | - Leon O. Murphy
- Casma Therapeutics, 400 Technology Sq, Cambridge, MA 02139, USA
| |
Collapse
|